Sign In
Learn bits
Science & Tech.
Mahesh

19/12/23 10:42 AM IST

The era of CRISPR therapeutics

In News
  • Recently, two highly anticipated CRISPR-based therapies for sickle-cell disease and β-thalassaemia in the U.K. and the U.S was approved.
CRISPR technology
  • The discovery of the CRISPR system was the result of almost three decades of pure academic pursuit.
  • Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA elements that Spanish researchers discovered in archaea in 1993, and named and described later in a number of bacterial genomes.
  • These elements contain pieces of genetic material derived from viruses that infect bacteria (i.e. bacteriophages) and a set of proteins called Cas, or CRISPR-associated.
  • Researchers tried to explain the elements’ effect on antiviral immunity in 2005, but later found that CRISPR + Cas proteins could detect and prevent viral infections.
  • That is, the two formed an antiviral defence system and helped bacteria ‘acquire’ resistance.
  • In 2010, scientists demonstrated that CRISPR + specific proteins called Cas9 had the ability to cut double-stranded DNA at specific points. They also found the RNAs molecules that guided the Cas9 proteins to specific positions on a genome.
  • The 2020 Nobel Prize didn’t only honour the researchers: it also symbolised the start of a time in which people couldn’t just read human genomes but also edit or modify the genetic code, with potentially long-lasting impacts on the future of medicine and genetic engineering.
CRISPR in medicine
  • The national regulator in the U.K., the Medicines and Healthcare products Regulatory Agency (MHRA), approved the use of a CRISPR-based method called exagamglogene autotemcel – sold under the brand ‘Casgevy’ – to treat sickle-cell disease and transfusion-dependent β-thalassemia.
  • The approval came after the MHRA evaluated safety and efficacy data in an ongoing clinical trial in 29 and 42 patients respectively.
  • The U.S. Food and Drug Administration also approved Casgevy to treat sickle-cell disease, rendering it one of the first CRISPR-based therapeutics to be approved by two major drug regulators.
  • In Casgevy, a patient’s blood stem cells are extracted, their genes modified to remove the defect that produces the sickling, and regrafted back. These cells then proliferate to produce normal red blood cells.
Concerns
  • None of these technologies are without caveats. Researchers have already reported several safety and accuracy issues.
  • An important one is off-target events: where a CRISPR-Cas9 system becomes inaccurate and edits some other part of the genome, with unintended consequences.
  • Many of these therapies are also too early in their development cycle.
  • Continued scrutiny and surveillance may yet reveal ‘side effects’ that we aren’t aware of today.
Source- The Hindu

More Related Current Affairs View All

23 Sep

Quad grouping

'Prime Minister Narendra Modi arrived in the United States, where he will participate in the fourth Quad Leaders Summit in Wilmington, Delaware.' Quad s the grouping of four de

Read More

21 Sep

India Achieves Tier 1 Status in Global Cybersecurity Index 2024

' India has secured Tier 1 status in the Global Cybersecurity Index (GCI) 2024, published by the International Telecommunication Union (ITU).' The GCI is a comprehensive assessm

Read More

21 Sep

A new White Revolution

'Operation Flood, launched in 1970, ushered in the White Revolution and transformed the dairy sector in India.' Dairy cooperatives procured 660 lakh kg of milk per day in 2023-2

Read More

India’s First Ai-Driven Magazine Generator

Generate Your Custom Current Affairs Magazine using our AI in just 3 steps